Skip to main content
    I

    IDEXX Laboratories Inc (IDXX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $690.24
    -10.41 (-1.49%)

    Market Cap: $55.48B

    Last updated: Nov 17, 2026 at 5:53 PM ET

    IDEXX Laboratories Inc (IDXX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    IDEXX Laboratories (IDXX) has a market cap of $55.48B and an enterprise value of $56.13B. Its return on invested capital of 44.29% compares with a 6.88% median across 12 similar companies.

    Total Valuation

    Enterprise value is 1.17% above the market cap, as debt exceeds cash.

    Market Cap$55.48B
    Enterprise Value$56.13B
    Latest price (Nov 17, 2026)$690.24

    Key Dates

    The next earnings report is expected on Feb 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 1, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.16% in the quarter ended Sep 30, 2026 and shrank 2.14% a year over 2 years.

    Shares Outstanding78.83M
    Shares Change (YoY)-1.59%
    Shares Change (QoQ)-0.16%
    Share Count Growth (2Y CAGR)-2.14%

    Valuation Ratios

    Sales and book value multiples are 11.7x and 29.1x. Its year-end P/E ranged from 36.8x to 77.4x from 2016 to 2025.

    P/E Ratio46.6x
    Forward P/E45.1x
    P/S Ratio11.7x
    Forward P/S11.7x
    P/B Ratio29.1x
    P/TBV Ratio49.0x
    P/FCF Ratio41.7x
    P/OCF Ratio39.1x
    PEG Ratio3.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 33.1x EBITDA and 42.2x free cash flow.

    EV / Earnings47.5x
    EV / Sales12.0x
    EV / EBITDA33.1x
    EV / EBIT37.3x
    EV / FCF42.2x

    Price Statistics

    The stock is up 0.04% over 52 weeks and trades 21.28% above its 50-day average.

    Beta (1Y)0.81
    52-Week Change+0.04%
    1-Month Change+24.19%
    3-Month Change+22.77%
    6-Month Change+26.30%
    5-Year Change-17.25%
    10-Year Change+414.48%
    Total Return (1Y)+0.04%
    Total Return (3Y CAGR)+14.18%
    Total Return (5Y CAGR)+1.72%
    Return vs SPY (1Y)-8.57%
    Max Drawdown (1Y)-34.17%
    Max Drawdown (3Y)-37.41%
    Sharpe Ratio (1Y)0.08
    Correlation with SPY (1Y)0.31
    50-Day Average$569.11
    200-Day Average$572.75
    52-Week Range$500.61 to $769.98
    RSI (14 Days)66.4
    Average Volume (20 Days)682.35K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.19x current liabilities, and total debt is 0.45x shareholder equity.

    Current Ratio1.19x
    Quick Ratio0.88x
    Debt / Equity0.45x
    Debt / EBITDA0.51x
    Debt / FCF0.65x
    Interest Coverage43.54x

    Returns and Efficiency

    Return on invested capital is 44.29% over the last 12 months, against a 5-year average of 40.17%.

    Return on Equity (ROE)63.25%
    Return on Assets (ROA)31.89%
    Return on Invested Capital (ROIC)44.29%
    Return on Capital Employed (ROCE)61.65%
    ROE (5Y Average)79.62%
    ROA (5Y Average)27.96%
    ROIC (5Y Average)40.17%
    Asset Turnover1.31x
    Inventory Turnover4.44x
    Receivables Turnover7.50x
    Cash Conversion Cycle101 days

    Taxes

    Income tax took 20.07% of pretax income over the last 12 months.

    Income Tax (TTM)$296.78M
    Effective Tax Rate20.07%

    Scores

    IDXX has an Altman Z-Score of 23.20, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score23.20
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $4.66B over the last 12 months is up 11.87% from the 12 months before.

    Revenue$4.66B
    Revenue Growth (YoY)+11.87%
    Gross Profit$2.92B
    Operating Income$1.51B
    Pretax Income$1.48B
    Net Income$1.18B
    EBITDA$1.66B
    EBIT$1.51B
    Reported EPS (TTM)$14.80

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 50.40% of the $3.71B in total assets.

    Cash and Equivalents$197.54M
    Total Debt$848.88M
    Net Debt$651.34M
    Net Debt Per Share$8.26
    Working Capital$235.78M
    Shareholder Equity$1.87B
    Book Value Per Share$23.71
    Tangible Book Value$1.11B
    Tangible Book Per Share$14.09
    Total Assets$3.71B
    Total Liabilities$1.84B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $114.99M of capital spending, operating cash flow left $1.30B of free cash flow.

    Operating Cash Flow$1.42B
    Capital Expenditures$114.99M
    Free Cash Flow$1.30B
    FCF Per Share$16.55
    Depreciation and Amortization$158.02M
    Share Repurchases$1.05B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 32.30%, against a 5-year average of 29.24%.

    Gross Margin62.72%
    Operating Margin32.30%
    Pretax Margin31.72%
    Net Margin25.36%
    EBITDA Margin35.69%
    EBIT Margin32.30%
    FCF Margin27.97%
    Gross Margin (5Y Average)60.19%
    Operating Margin (5Y Average)29.24%
    Net Margin (5Y Average)22.76%

    Growth

    Revenue grew 8.52% a year over 3 years, and EPS 17.63% a year.

    Revenue Growth (3Y CAGR)+8.52%
    Revenue Growth (5Y CAGR)+9.72%
    EPS Growth (3Y CAGR)+17.63%
    EPS Growth (5Y CAGR)+15.14%
    FCF Growth (3Y CAGR)+38.94%
    FCF Growth (5Y CAGR)+14.33%
    Operating Income Growth (3Y CAGR)+14.81%
    Book Value Per Share Growth (2Y CAGR)+6.07%
    Tangible Book Per Share Growth (2Y CAGR)+4.31%

    Revenue and profit by year

    Dividends and Yields

    IDXX does not pay a dividend. Its free cash flow yield is 2.40%.

    Earnings Yield2.15%
    FCF Yield2.40%
    Buyback Yield1.74%
    Shareholder Yield1.74%

    Stock Splits

    The last split was a 2-for-1 forward split on Jun 16, 2015.

    Last Split DateJun 16, 2015
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 11 similar companies, IDXX has the highest P/E.

    P/E Ratio46.6x vs 27.1x median
    P/S Ratio11.7x vs 5.9x median
    ROIC44.29% vs 6.88% median
    Revenue Growth (Trailing 4 Quarters, YoY)+11.87% vs +6.27% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.69% and EPS growth at 13.69% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.69%
    EPS Growth Forecast (2Y CAGR)+13.69%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IDXX

    What is IDXX's market cap?

    IDEXX Laboratories has a market cap of $55.48B. Its enterprise value, which adds debt and subtracts cash, is $56.13B.

    What is IDXX's P/E ratio?

    IDEXX Laboratories has a trailing P/E ratio of 46.6x and a forward P/E of 45.1x.

    How many shares of IDXX are outstanding?

    IDEXX Laboratories has 78.83M shares outstanding. The count is down 1.59% from a year earlier.

    Does IDXX pay a dividend?

    No. IDEXX Laboratories does not pay a dividend.

    How much debt does IDXX have?

    IDEXX Laboratories has $848.88M of total debt and $197.54M of cash and equivalents, a net debt position of $651.34M.